Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clin...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

hiTHit Feb. 3 at 3:41 PM

$PULM The price is falling upwards.

0 · Reply

Nakom Feb. 3 at 3:33 PM

$PULM Batman and Robin still sticking around.

0 · Reply

HomeRunHitterXXXXX Feb. 3 at 4:11 AM

$PULM

0 · Reply

Shockabilly Feb. 3 at 3:25 AM

$PULM only a dum dum would buy this trash stock. one dude keeps pulling money form this whenever he's able to get a pump on it. it became a chronic short scam by some dude with enough volume to manipulate it. He uses this page along with his massive bot farm to manipulate users of this website. i claim i know his identity. But i also claim to be hunting for the Sabbatian Antichrist and that i'm a messianic doomsday figure. oooga booga. #dontbuypulm

0 · Reply

cb5000calls Feb. 2 at 9:15 PM

$SLS SLS runs first → eyes come to the sector → money rotates into beaten-down biotechs → PULM first, BDRX last SLS is leading with strength, PULM is coiled, BDRX is lagging — exactly how a Batman/Robin basket is supposed to look. @Love_To_Learn is this correct? Charts line up with the Batman/Robin take. SLS already broke trend and is consolidating on volume — leader behavior. PULM basing post-flush, BDRX still lagging. If capital rotates, order matters. $BDRX $PULM

2 · Reply

Love_To_Learn Feb. 2 at 9:02 PM

$BDRX coding batman robin $SLS $PULM

0 · Reply

Love_To_Learn Feb. 2 at 3:38 PM

$BDRX EXECUTING BATMAN ROBIN $PULM

1 · Reply

HomeRunHitterXXXXX Feb. 1 at 4:18 AM

$PULM where’s ohno 😳

0 · Reply

Nakom Jan. 31 at 2:55 PM

$PULM Did you know if a buyer comes forward and wants to buy the assets shareholders need to vote on the approval of sale price of assets???

0 · Reply

HomeRunHitterXXXXX Jan. 30 at 2:59 PM

$PULM v

0 · Reply

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Oct 16, 2025, 8:05 AM EDT - 3 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 6 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

May 15, 2025, 8:05 AM EDT - 9 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 9 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 11 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 1 year ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 2 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 12:45 PM EDT - 4 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 9, 2021, 9:00 AM EST - 4 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Aug 10, 2021, 9:10 AM EDT - 4 years ago

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Jul 27, 2021, 10:00 AM EDT - 4 years ago

Pulmatrix appoints Director Anand Varadan

hiTHit Feb. 3 at 3:41 PM

$PULM The price is falling upwards.

0 · Reply

Nakom Feb. 3 at 3:33 PM

$PULM Batman and Robin still sticking around.

0 · Reply

HomeRunHitterXXXXX Feb. 3 at 4:11 AM

$PULM

0 · Reply

Shockabilly Feb. 3 at 3:25 AM

0 · Reply

cb5000calls Feb. 2 at 9:15 PM

2 · Reply

Love_To_Learn Feb. 2 at 9:02 PM

$BDRX coding batman robin $SLS $PULM

0 · Reply

Love_To_Learn Feb. 2 at 3:38 PM

$BDRX EXECUTING BATMAN ROBIN $PULM

1 · Reply

HomeRunHitterXXXXX Feb. 1 at 4:18 AM

$PULM where’s ohno 😳

0 · Reply

Nakom Jan. 31 at 2:55 PM

$PULM Did you know if a buyer comes forward and wants to buy the assets shareholders need to vote on the approval of sale price of assets???

0 · Reply

HomeRunHitterXXXXX Jan. 30 at 2:59 PM

$PULM v

0 · Reply

Nakom Jan. 30 at 2:43 PM

$PULM Maybe quiet deal over the weekend. 🤐.

1 · Reply

Love_To_Learn Jan. 29 at 10:09 PM

$PULM WILL NEED U NOW THAT I DUMPED SOME $SLS TRANSFERS

1 · Reply

HomeRunHitterXXXXX Jan. 29 at 8:08 PM

$PULM

0 · Reply

Nakom Jan. 29 at 7:31 PM

$PULM Could this Monday be the Merger Monday we have been waiting for the past year. Stay tuned. I’m naming this coming Monday Fabulous February Monday!!!

1 · Reply

HomeRunHitterXXXXX Jan. 29 at 3:52 PM

$PULM

0 · Reply

HomeRunHitterXXXXX Jan. 29 at 1:56 PM

$PULM when’s the merger? Sale of assets to Mannkind?

0 · Reply

Nakom Jan. 29 at 1:29 PM

$PULM Let’s go Pulmatrix!!! Super bullish.

0 · Reply

HomeRunHitterXXXXX Jan. 29 at 1:54 AM

$PULM

0 · Reply

Nakom Jan. 28 at 10:43 PM

$PULM Maybe merger Monday is coming very soon!!!

0 · Reply

HomeRunHitterXXXXX Jan. 28 at 8:36 PM

$PULM where is skid mark Mo hiding?

0 · Reply

HomeRunHitterXXXXX Jan. 28 at 12:15 PM

$PULM

0 · Reply

HomeRunHitterXXXXX Jan. 28 at 5:18 AM

$PULM mo or homo?

0 · Reply

Market Cap	9.38M
Revenue (ttm)	7.81M
Net Income (ttm)	-9.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-122.41%
Debt to Equity Ratio	0.00

Volume	13,500
Avg Vol	21,184
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	24%
Beta	1.67
Analysts	Strong Buy
Price Target	$10.00